Molecure S.A. (WSE:MOC)

Market Cap	152.37M
Revenue (ttm)	1.52M
Net Income (ttm)	-30.75M
Shares Out	16.84M
EPS (ttm)	-1.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,312
Average Volume	33,225
Open	9.16
Previous Close	9.16
Day's Range	9.00 - 9.25
52-Week Range	8.31 - 20.15
Beta	2.39
RSI	41.42
Earnings Date	Mar 28, 2025

About Molecure

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 111
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: MOC

Financial Performance

In 2023, Molecure's revenue was 3.65 million, a decrease of -51.39% compared to the previous year's 7.51 million. Losses were -28.37 million, -21.08% less than in 2022.